NL267508A - - Google Patents

Info

Publication number
NL267508A
NL267508A NL267508DA NL267508A NL 267508 A NL267508 A NL 267508A NL 267508D A NL267508D A NL 267508DA NL 267508 A NL267508 A NL 267508A
Authority
NL
Netherlands
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of NL267508A publication Critical patent/NL267508A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NL267508D 1960-07-26 NL267508A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4529260A 1960-07-26 1960-07-26
US118261A US3176019A (en) 1960-07-26 1961-06-20 Substituted aminobutynyl acetates

Publications (1)

Publication Number Publication Date
NL267508A true NL267508A (enExample)

Family

ID=26722613

Family Applications (2)

Application Number Title Priority Date Filing Date
NL267508D NL267508A (enExample) 1960-07-26
NL124473D NL124473C (enExample) 1960-07-26

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL124473D NL124473C (enExample) 1960-07-26

Country Status (9)

Country Link
US (1) US3176019A (enExample)
BE (1) BE606560A (enExample)
CH (1) CH421078A (enExample)
DE (1) DE1216866B (enExample)
DK (1) DK113854B (enExample)
ES (1) ES269353A1 (enExample)
FR (1) FR1325M (enExample)
GB (1) GB940540A (enExample)
NL (2) NL124473C (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US3864388A (en) * 1970-12-29 1975-02-04 Sumitomo Chemical Co Alkynyl esters of {60 -alkoxy-{60 -phenyl alkenoic acid
US5036107A (en) * 1986-06-27 1991-07-30 Marion Merrell Dow Inc. 1,7-substituted heptyn-2-ones and use
US4957941A (en) * 1987-11-16 1990-09-18 United Pharmaceuticals, Inc. Anti-spasmdoic agents having an acetylenic bond
IL91377A (en) * 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO1998001125A2 (en) * 1996-07-09 1998-01-15 Sepracor, Inc. Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
US6140529A (en) * 1998-10-22 2000-10-31 Sepracor Inc. Synthesis of optically active cyclohexylphenylglycolate esters
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN1438861A (zh) * 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
EP1461306B1 (en) 2001-10-26 2008-12-24 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds and their use as antimuscarinic agents
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
DE60226906D1 (de) * 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
AU2002321711A1 (en) * 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
WO2004018422A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
TW200412945A (en) 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
DE60227576D1 (de) 2002-12-10 2008-08-21 Ranbaxy Lab Ltd 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
EP1583741A1 (en) * 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7517905B2 (en) * 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006514978A (ja) * 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2522071A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
US20080319002A1 (en) * 2004-06-16 2008-12-25 Ranbaxy Laboratories Limited Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
WO2006018708A2 (en) * 2004-08-19 2006-02-23 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A2 (en) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1828174A1 (en) * 2004-11-19 2007-09-05 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
WO2009122429A2 (en) * 2008-02-04 2009-10-08 Matrix Laboratories Limited Crystalline oxybutynin and process for preparing the same
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2013119910A1 (en) 2012-02-09 2013-08-15 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
SI3746126T1 (sl) 2018-01-30 2025-01-31 Apnimed, Inc. (Delaware) Postopki in sestavki za zdravljenje spalne apneje ali preprostega smrčanja
US12448347B2 (en) 2020-05-05 2025-10-21 Apnimed, Inc. (Delaware) Polymorphic forms of (R)-oxybutynin hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE895595C (de) * 1943-09-29 1953-11-05 Basf Ag Verfahren zur Herstellung von Aminoalkinolen
DE1003209B (de) * 1953-03-24 1957-02-28 Basf Ag Verfahren zur Herstellung spasmolytisch wirksamer basischer Carbinole
US2867619A (en) * 1956-11-05 1959-01-06 Lakeside Lab Inc Aminoalkynyl-n-alkylpiperidine carboxylates
DE1083254B (de) * 1957-04-01 1960-06-15 Lakeside Lab In Verfahren zur Herstellung von blutdrucksenkenden N-disubstituierten Diaminoalkinen, deren Saeureadditionssalzen oder quaternaeren Ammoniumsalzen
DE1100617B (de) * 1959-10-22 1961-03-02 Basf Ag Verfahren zur Herstellung von 1-Dialkylamino-4-hydroxy-acetylenen-(2)

Also Published As

Publication number Publication date
GB940540A (en) 1963-10-30
ES269353A1 (es) 1961-11-16
CH421078A (de) 1966-09-30
DE1216866B (de) 1966-05-18
US3176019A (en) 1965-03-30
DK113854B (da) 1969-05-05
BE606560A (fr) 1962-01-26
NL124473C (enExample)
FR1325M (fr) 1962-05-21

Similar Documents

Publication Publication Date Title
AT219790B (enExample)
CH723861A4 (enExample)
CH1244360A4 (enExample)
BE565012A (enExample)
BE586283A (enExample)
BE588858A (enExample)
BE592862A (enExample)
BE593203A (enExample)
BE594790A (enExample)
BE594974A (enExample)
BE595430A (enExample)
BE595827A (enExample)
BE596133A (enExample)
BE597003A (enExample)
BE598233A (enExample)
BE598893A (enExample)
BE598943A (enExample)
BE599007A (enExample)
BE599143A (enExample)
BE599155A (enExample)
BE599409A (enExample)
BE599444A (enExample)
BE599685A (enExample)
BE599711A (enExample)
BE600035A (enExample)